Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Letters: Comments and Responses

Lipids and Glucose in Type 2 Diabetes: What About the β-Cell and the Mitochondria?

Response to Eldor and Raz

  1. Guenther Boden, MD1 and
  2. Markku Laakso, MD2
  1. 1Temple University Health Science Center, General Clinical Research Center, Philadelphia, Pennsylvania
  2. 2Kuopio University Hospital, Kuopio, Finland
  1. Address correspondence to Dr. Guenther Boden, MD, Temple University Health Science Center, General Clinical Research Center, North Broad St., 4W, Philadelphia, PA 19140. E-mail: guenther.boden{at}tuhs.temple.edu
Diabetes Care 2005 Apr; 28(4): 986-987. https://doi.org/10.2337/diacare.28.4.986
PreviousNext
  • Article
  • Info & Metrics
  • PDF
Loading

Response to Eldor and Raz

Drs. Eldor and Raz (1) assert that “high levels of FFAs [free fatty acids] have a detrimental effect on β-cell survival and insulin secretion.” We agree, but only in relation to patients who have dysfunctional β-cells, i.e., patients with pre-diabetes, impaired glucose tolerance, or type 2 diabetes (2–5). On the other hand, in people with normally functioning β-cells, there is much evidence that FFAs, rather than impairing, actually augment insulin secretion. For instance, several groups have recently shown that in healthy individuals, elevation of plasma FFAs, for as long as 96 h, potentiated glucose-stimulated insulin secretion (2,6–8). Moreover, lowering plasma FFA levels, rather than improving insulin secretion, has been shown to actually decrease insulin secretion (9,10). Thus, there is currently little evidence to support the concept of FFA-induced β-cell lipotoxicity in normal human subjects. Moreover, the concept of β-cell lipotoxicity would be difficult to reconcile with the observation that >50% of obese people with chronically elevated FFA levels never develop type 2 diabetes during their lifetime, despite the fact that most of them are insulin resistant.

Drs. Eldor and Raz also state that lipotoxicity-induced mitochondrial damage is a “core process in the pathogenesis of type 2 diabetes.” We agree that there is mitochondrial dysfunction in patients with pre-diabetes as well as in patients with diabetes. It is not known, however, whether this is a primary or secondary defect. Moreover, whereas it is possible, perhaps even likely, that high fatty acid levels contribute to mitochondrial dysfunction, to our knowledge, there are presently no human data to support this assertion.

Footnotes

  • DIABETES CARE

References

  1. ↵
    Eldor R, Raz I: Lipids and glucose in type 2 diabetes: what about the β-cell and the mitochondria? (Letter). Diabetes Care 28:985–986, 2005
  2. ↵
    Kashyap S, Belfort R, Gastaldelli A, Pratipanawatr T, Berria R, Pratipanawatr W, Bajaj M, Mandarino L, DeFronzo R, Cusi K: A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes 52:2461–2474, 2003
    OpenUrlAbstract/FREE Full Text
  3. Storgaard H, Jensen CB, Vaag AA, Volund A, Madsbad S: Insulin secretion after short- and long-term low grade free fatty acid infusion in men with increased risk of developing type 2 diabetes. Metabolism 52:885–894, 2003
    OpenUrlCrossRefPubMedWeb of Science
  4. Stefan N, Stumvoll M, Bogardus C, Tataranni PA: Elevated plasma nonesterified fatty acids are associated with deterioration of acute insulin response in IGT but not NGT. Am J Physiol Endocrinol Metab 284:E1156–E1161, 2003
    OpenUrlAbstract/FREE Full Text
  5. ↵
    Boden G, Chen X: Effects of fatty acids and ketone bodies on basal insulin secretion in type 2 diabetes. Diabetes 48:577–583, 1999
    OpenUrlAbstract
  6. ↵
    Boden G, Chen X, Rosner J, Barton M: Effects of a 48-h fat infusion on insulin secretion and glucose utilization. Diabetes 44:1239–1242, 1995
    OpenUrlAbstract/FREE Full Text
  7. Jensen CB, Storgarrd H, Holst JJ, Dela F, Madsbad S, Vaag AA: Insulin secretion and cellular glucose metabolism after prolonged low-grade intralipid infusion in young men. J Clin Endocrinol Metab 88:2775–2783, 2003
    OpenUrlCrossRefPubMedWeb of Science
  8. ↵
    Carpentier A, Giacca A, Lewis GF: Effect of increased plasma non-esterified fatty acids (NEFAs) on arginine-stimulated insulin secretion in obese humans. Diabetologia 44:1989–1997, 2001
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    Dobbins RL, Chester MW, Daniels MB, McGarry JD, Stein DT: Circulating fatty acids are essential for efficient glucose-stimulated insulin secretion after prolonged fasting in humans. Diabetes 47:1613–1618, 1998
    OpenUrlAbstract
  10. ↵
    Boden G, Chen X, Iqbal N: Acute lowering of plasma fatty acids lowers basal insulin secretion in diabetic and nondiabetic subjects. Diabetes 47:1609–1612, 1998
    OpenUrlAbstract
PreviousNext
Back to top
Diabetes Care: 28 (4)

In this Issue

April 2005, 28(4)
  • Table of Contents
  • About the Cover
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Lipids and Glucose in Type 2 Diabetes: What About the β-Cell and the Mitochondria?
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Lipids and Glucose in Type 2 Diabetes: What About the β-Cell and the Mitochondria?
Guenther Boden, Markku Laakso
Diabetes Care Apr 2005, 28 (4) 986-987; DOI: 10.2337/diacare.28.4.986

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Lipids and Glucose in Type 2 Diabetes: What About the β-Cell and the Mitochondria?
Guenther Boden, Markku Laakso
Diabetes Care Apr 2005, 28 (4) 986-987; DOI: 10.2337/diacare.28.4.986
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Footnotes
    • References
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Primary Aldosteronism in Diabetic Subjects With Resistant Hypertension
  • Primary Aldosteronism in Diabetic Subjects With Resistant Hypertension
  • Flexible Intensive Insulin Therapy in Adults With Type 1 Diabetes and High Risk for Severe Hypoglycemia and Diabetic Ketoacidosis
Show more Letters: Comments and Responses

Similar Articles

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.